65.56
0.55%
+0.36
After Hours:
65.56
Lantheus Holdings Inc stock is currently priced at $65.56, with a 24-hour trading volume of 580.57K.
It has seen a +0.55% increased in the last 24 hours and a +11.59% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $64.74 pivot point. If it approaches the $65.73 resistance level, significant changes may occur.
Previous Close:
$65.20
Open:
$65.41
24h Volume:
580.57K
Market Cap:
$4.49B
Revenue:
$1.30B
Net Income/Loss:
$326.66M
P/E Ratio:
45.85
EPS:
1.43
Net Cash Flow:
$258.71M
1W Performance:
+2.74%
1M Performance:
+11.59%
6M Performance:
-0.21%
1Y Performance:
-22.77%
Lantheus Holdings Inc Stock (LNTH) Company Profile
Name
Lantheus Holdings Inc
Sector
Phone
978-671-8001
Address
331 Treble Cove Road, North Billerica, MA
Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-18-23 | Downgrade | William Blair | Outperform → Mkt Perform |
Dec-04-23 | Initiated | TD Cowen | Outperform |
Sep-29-23 | Initiated | William Blair | Outperform |
Mar-08-23 | Initiated | JMP Securities | Mkt Outperform |
Nov-30-22 | Initiated | SVB Leerink | Outperform |
Oct-13-22 | Initiated | Mizuho | Buy |
May-09-22 | Initiated | B. Riley Securities | Buy |
Apr-13-22 | Initiated | Truist | Buy |
Feb-01-21 | Initiated | SVB Leerink | Outperform |
Jun-29-20 | Resumed | Jefferies | Buy |
Aug-16-19 | Upgrade | CJS Securities | Market Perform → Market Outperform |
Nov-02-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
Nov-08-16 | Reiterated | RBC Capital Mkts | Outperform |
Sep-23-16 | Resumed | Credit Suisse | Neutral |
Feb-24-16 | Reiterated | RBC Capital Mkts | Outperform |
Dec-11-15 | Downgrade | Credit Suisse | Outperform → Neutral |
Sep-30-15 | Downgrade | Wells Fargo | Outperform → Market Perform |
Jul-20-15 | Initiated | Credit Suisse | Outperform |
Jul-20-15 | Initiated | Jefferies | Buy |
Jul-20-15 | Initiated | RBC Capital Mkts | Outperform |
Jul-20-15 | Initiated | Robert W. Baird | Outperform |
Jul-20-15 | Initiated | Wells Fargo | Outperform |
View All
Lantheus Holdings Inc Stock (LNTH) Latest News
Here's Why Lantheus Holdings (LNTH) Gained But Lagged the Market Today
Zacks Investment Research
Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings
Zacks Investment Research
Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?
Zacks Investment Research
Lantheus Holdings (LNTH) Outpaces Stock Market Gains: What You Should Know
Zacks Investment Research
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
Zacks Investment Research
Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research
Lantheus Holdings Inc Stock (LNTH) Financials Data
Lantheus Holdings Inc (LNTH) Revenue 2024
LNTH reported a revenue (TTM) of $1.30 billion for the quarter ending December 31, 2023, a +38.65% rise year-over-year.
Lantheus Holdings Inc (LNTH) Net Income 2024
LNTH net income (TTM) was $326.66 million for the quarter ending December 31, 2023, a +1,064% increase year-over-year.
Lantheus Holdings Inc (LNTH) Cash Flow 2024
LNTH recorded a free cash flow (TTM) of $258.70 million for the quarter ending December 31, 2023, a -1.80% decrease year-over-year.
Lantheus Holdings Inc (LNTH) Earnings per Share 2024
LNTH earnings per share (TTM) was $4.64 for the quarter ending December 31, 2023, a +1,265% growth year-over-year.
About Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Cap:
|
Volume (24h):